Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Uberti, Joseph P  [Clear All Filters]
2023
Modi D, Alkassis S, Kim S, Kin A, Deol A, Ayash L, Ratanatharathorn V, Uberti JP. Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission. Leuk Lymphoma. 2023:1-10.
2021
Albanyan O, Alkassis S, Kim S, Kin A, Alavi A, Ayash L, Ratanatharathorn V, Modi D, Uberti JP, Deol A. Impact of pre-transplant induction therapy on outcomes of patients who undergo autologous stem cell transplantation for mantle cell lymphoma in first complete remission. Hematol Oncol Stem Cell Ther. 2021.
Modi D, Chi J, Kim S, Deol A, Ayash L, Ratanatharathorn V, Uberti JP. Outcomes of Fludarabine, Melphalan and Total Body Irradiation as a Reduced Intensity Conditioning Regimen in Matched Donor Allogeneic Peripheral Blood Stem Cell Transplantation: Outcomes of Flu-Mel-TBI. Transplant Cell Ther. 2021.
2019
Modi D, Surapaneni M, Kim S, Ayash L, Alavi A, Ratanatharathorn V, Deol A, Uberti JP. Allogeneic stem cell transplant provides durable response in peripheral T-cell lymphoma. Leuk Res. 2019;83:106171.
Modi D, Kim S, Surapaneni M, Ayash L, Alavi A, Ratanatharathorn V, Deol A, Uberti JP. R-BEAM versus Reduced Intensity Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma. Biol Blood Marrow Transplant. 2019.
2018
Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, J Rizzo D, Anderlini P, Leitman SF, Varni JW, Kobusingye H, et al. The Effect of Aging and Pre-Donation Comorbidities on the Related PBSC Donor Experience: A Report from the Related Donor Safety Study (RDSafe). Biol Blood Marrow Transplant. 2018.
2014
Veeraputhiran M, Jain T, Cronin S, Al-Kadhimi Z, Abidi MH, Ayash L, Mellert K, Lum LG, Ratanatharathorn V, Uberti JP, et al. Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant. J Clin Apher. 2014.
2013
Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Bin Chen Y-, Kaminski MS, H Holland K, Winter JN, Mason JR, et al. Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. J Clin Oncol. 2013.